Pacira’s Long Day With Exparel

 
• By Michael McCaughan

Many an unfortunate NDA sponsor has faced a long day when heading into US FDA advisory committee review. But Pacira faced a really long day for the review of a supplemental indication of Exparel. In fact, it was a day and a half. 

Business time concept as a group of running businessmen and businesswomen using a giant clock to cross over a cliff as a bridge as a metaphor for schedule and appointment speed as a 3D illustration.

More from US FDA Performance Tracker

More from Regulatory Trackers